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G Proteins in the Heart
A Redundant and Diverse Transmembrane Signaling Network
Stephan R. Holmer, MD, and Charles J. Homcy, MD G proteins, or GTP-binding proteins, are a family of proteins that act as links in signaling chains across cell membranes in all eukaryotic cells.1-3 These pathways usually include a receptor molecule, a G protein as the signal transducer, and an effector enzyme or ion channel that can be activated or inhibited by the G protein. A large variety of stimuli reaching the cell surface, including numerous neurohumoral and olfactory signals and light, can be transmitted by these specific signaling mechanisms. It is remarkable that this diversity of signals is processed by structurally similar transducing mechanisms, including the activation of a GTP-binding protein. From sequence and structure analyses, we know that receptors that transduce a signal through the activation of a G protein share a common structure consisting of seven transmembrane-spanning domains, intracellular and extracellular loops, an extracellular amino terminus, and a cytoplasmic carboxy terminus. 3 The cytoplasmic loops, particularly the third cytoplasmic loop, and the carboxy terminus appear to be involved in G protein coupling. G proteins also share a common structure, which is heterotrimeric, consisting of an a!,B/ y-subunit; the a-subunit is thought to be responsible for the specific action by directly interacting with the effector. In addition, the a-subunit binds and subsequently hydrolyzes GTP, the important events that first activate and then deactivate the G protein.
Since the first evidence of a GTP-dependent step forms of Gi exist and are expressed in a tissue-dependent manner8; their individual functions have not been fully clarified. A heterotrimeric G protein called transducin is located in the outer segments of retinal rods and transduces the signal from the light-activated rhodopsin to the cyclic GMP (cGMP)-phosphodiesterase. 9 There are other G proteins that activate membrane-bound phospholipase C.10 G proteins play a major role in the modulation of ion channels,11 including a K' channel, which can be activated by a Gi,12 and voltage-dependent Ca 2 channels and Na+ channels, which can be positively or negatively regulated by GQ, respectively.1314 A G protein termed Go is expressed in high quantities in brain.15 It may be involved in K' channel opening,16 regulation of opioid-mediated Ca 2 channels, and stimulation of phospholipase C.17 Important signal transduction in olfaction is mediated by a G protein called GQf whose a-subunit shows an 88% homology with the a-subunit of GS. 18 An additional large number of other GTP-binding proteins exist, some of them resembling small-molecular-weight species like the ras proteins.1920 In the larger-molecularweight range, complementary DNA (cDNA) cloning has demonstrated the existence of several more proteins that are homologous to the described a-subunits found in heterotrimeric G proteins. 21 Their specific functions have yet to be determined.
Some G proteins appear to be able to interact with more than one receptor as well as with more than one cellular effector, indicating that a diversity of signals may result in the same cellular response and, conversely, that a single stimulus can trigger several cellular reactions. The resulting effect probably depends on the differential expression of the G proteins and effector proteins in various cell types as well as the stoichiometry of the components of the signaling pathways, which is known to vary among tissues and cell types. 25 The binding of GTP also mediates a conformational change of the a-subunit leading to the release of the 8//y complex from the now-activated a-subunit. This a-subunit stimulates the effector molecule -an enzyme or ion channel-by direct interaction. The GTPase activity of the a-subunit then hydrolyzes GTP, releasing the y-phosphate group. This increases the affinity of 1B and y for the a-subunit; they now reassociate, leaving the G protein in the inactive form. Thus, the G protein can enter a new activation cycle. An alternative hypothesis has been suggested by Marbach For the activation process, the stoichiometry of receptor and G protein appears to be of particular interest. Usually, the G protein is found in excess (as much as 10-fold) relative to a specific receptor. The interaction of receptor with G protein is dependent on this stoichiometry. The receptor forms a highaffinity state for agonists when interacting with a G protein that can be detected under conditions in which the G protein is in a transitory state that is not guanine nucleotide bound. This interaction and subsequent catalytic activity of the receptor to promote GDP-GTP exchange is the physiologically important role of the receptor. The high-affinity state of the receptor can be used as a measure of the receptors that can interact with a G protein efficiently. The fraction of high-affinity receptors may be limited by the concentration of available G proteins, and an increase in receptor number can result in a reduction of the fraction of high-affinity (G protein-coupled) receptors. 30 Conversely, a reduction of the G protein number or a functional loss of G protein activity in the membrane can affect receptor-G protein coupling and impair receptor-mediated activation of the signal transduction pathway despite the fact that the G protein is still in excess. 31 Structure-Function Relation and Homology Among a-Subunits Because the G protein a-subunit carries out several distinct functions during the activation and deactivation cycle (i.e., interaction with other proteins and its own enzymatic activity), a major focus of G protein research has been to correlate structural and functional properties of the protein (Figure 2 The lowest degree of sequence homology among different G proteins is found in three regions -at the very N terminus, in a region encompassing amino acids 80-150, and in a region approximately 50 amino acids from the carboxy terminus. The latter region is probably responsible for the specificity of receptor interaction, whereas the region in the middle of the protein may encompass the specific effector-binding domain. The involvement of additional regions in effector coupling, including the amino and carboxy termini, has been suggested in experiments in which chimeric as/ai molecules have been expressed in cultured cell lines.39,40 The amino terminus may also encompass the domain responsible for interaction with f3/y complex.41 '42 Even the isoforms of Gia show an increased diversity in these regions, while sharing almost complete homology in the others.8 '43 This heterogeneity located at certain "hot spots" further supports the hypothesis that these regions are responsible for the specific function of the G protein and thus reveal a close structure-function relation.
G Proteins in the Heart and Their Functions Many G proteins have been found in the heart that serve to transduce signals that regulate myocardial functions, including contractility, chronotropy, and dromotropy. 2 The ,B-adrenergic receptor-adenylyl cyclase system has been of particular interest in the heart because by production of the second-messenger cyclic AMP (cAMP) and Of other known G proteins, Go is found to be expressed in the heart at a rather low level, mainly in the atria and even less in the ventricle,75 compared with its high level of expression in brain. Changes of Go in diseases of the heart have not been described.
A number of small GTP-binding proteins are found in the heart. Their functions, however, are not fully understood. Their involvement has been postulated in intracellular signaling processes such as secretion (e.g., of atrial natriuretic peptide) as has been described for intracellular transport mechanisms in yeast and mammalian cells.76 Further studies, including molecular cloning of their cDNAs or genes and structure-function analysis, are needed to evaluate their role in the regulation of cardiac function. Recently, there have been data to suggest that the ras protein and its GTPase-activating protein may by guest on June 9, 2017 http://circ.ahajournals.org/ Downloaded from play a role in receptor-mediated modulation of ion channel activity. 77 ffly Subunits of G Proteins Upon activation of the G protein, the ,B-and y-subunits remain tightly associated with each other after dissociation from the a-subunit. They are probably shared among different a-subunits. The functional association of an a-subunit with a P,ly complex is required for the interaction of the a-subunit with a catalytic receptor; thus, P,ly subunits play a major role in the activation step of a G protein. Their important role in modulating the activity of the a-subunit has been discussed earlier. There can be no doubt that the stoichiometry of P/y-relative to a-subunits is a crucial determinant of the steady state of G protein activation and deactivation. More quantitative measurements, however, are needed because the role of subunit stoichiometry in determining the overall efficiency of receptor-triggered G protein activation remains poorly defined.
A controversial issue relates to the role of Pfly in the activation of atrial muscarinic K' channels. Logothetis and coworkers78 originally suggested that these subunits could directly gate atrial K' channels. However, results from other investigators were in disagreement with these findings and indicated that the a-subunit, not the p,ly-subunit, was responsible for K' channel activation by G.12 There has, however, been evidence that the ffly-subunits can activate cardiac K' channels via activation of phospholipase A2. 79 Two distinct forms of p-subunits have been known for some time to exist in G5, Gi and G. is still not known whether the P-isoforms are functionally distinct. There is evidence that retinal transducin is the only G protein using only one subunit, the 36-kd species 813, whereas in purified preparations of other G proteins, other isoforms are detectable. This supports the hypothesis that an as-yetunknown functional specificity of the subunits may exist. The functional properties of the y-subunits are the least well characterized. Transducin-y, a polypeptide of 74 amino acids, appears to be distinct from the y-subunits of other G proteins. The existence of a family of G protein y-subunits, suggested initially by immunological studies, has now been proven by cDNA cloning.82 The y-subunits are thought to play a role as a membrane anchor of the heterotrimer, possibly as a result of a posttranslational modification. Recently, they have been shown to undergo carboxy terminal isoprenylation, which probably plays a role in this process. 83 Changes in G Protein Function and Stoichiometry in Cardiovascular Disease The adrenergic signaling mechanism can become dysfunctional in a variety of disease processes that affect the heart, including heart failure and ischemia. Changes in adrenergic drive have been described in heart failure in humans and in animal models of heart failure and include a downregulation of p-adrenergic receptor content and decreased adenylyl cyclase activity.84 These changes, resulting in decreased cAMP production, are thought to be responsible for a decreased responsiveness of the failing myocardium to endogenous as well as therapeutically administered catecholamines and for deteriorating myocardial function.
However, not all experimental models in which a decreased adenylyl cyclase activity is found also have a concomitant decrease in p-adrenergic receptor density. It is interesting that studies from the era before the discovery of G proteins supported the existence of a postreceptor defect in the adenylyl cyclase system in heart failure. 85 In papillary muscles from patients with heart failure, the positive inotropic effect of glucagon, which activates adenylyl cyclase via a glucagon receptor and G, (i.e., independent of the pB-adrenergic system), was markedly attenuated, as was the p-adrenergic effect. In more recent studies in a heart failure model of chronic pressure overload in dogs resulting from aortic stenosis, a significant decrease in high-affinity p-adrenergic agonist-binding sites has been found, pointing to a possible role of the coupling G protein, GQ, or to an alteration of the receptor itself.53 In the same model, G, activity was decreased by approximately 40-50% of control levels as determined by functional reconstitution using membranes from S49 cyccells.31 Similar findings were obtained in conscious dogs in which ischemic ventricular myocardium was compared with the nonischemic region after 1 hour of coronary artery occlusion.86 Ischemia caused an attenuated adenylyl cyclase activity and a decrease in G, activity, whereas the number of 8-adrenoceptors was increased. The majority of these receptors, however, were also uncoupled from GQ. Data reported. The molecular reason for this loss in function has yet to be determined in the models studied. Mechanisms involving posttranslational modification such as ribosylation or phosphorylation may be important in this regulation of protein activity during the development of heart disease.
In an attempt to understand the processes that lead to the development of postreceptor defects of the adrenergic nervous system in the heart, the effect of chronic norepinephrine exposure on this same pathway was studied in a conscious animal model. 88 Although the molecular details of the acute desensitization process have been extremely well defined, little information is available on the effects of chronic catecholamine exposure on the adrenergic signaling pathway in vivo. This is particularly important because the cardiac sympathetic nerves play a major role in regulating the exposure of postsynaptic receptors to circulating catecholamines. In fact, some of the changes that occur in human heart failure at the level of the /3-adrenergic receptor may require abnormal or malfunctioning cardiac sympathetic nerves for development. In this model of prolonged norepinephrine exposure in conscious dogs, an actual increase in ,3-adrenergic receptor density was observed with a reduction in functional GS and adenylyl cyclase activity. The ,B-adrenergic receptors were also found to be in a predominantly low-affinity or uncoupled state. Thus, these different pathophysiological states (heart failure, ischemia, and prolonged agonist exposure) showed the same phenotype-increased /3-adrenergic receptor density and decreased Gs and adenylyl cyclase activities-suggesting that a common but unidentified mechanism may mediate these postreceptor abnormalities. Evidence from our laboratory indicates that a decrease in G, functional activity occurs with the development of cardiac hypertrophy before heart failure ensues. Furthermore, this reduction is paralleled by a decrease of similar magnitude in G,a mRNA levels.89 However, as systolic heart failure and left ventricular dilatation ensue, an additional and even more marked decrease in adenylyl cyclase activity occurs without a further reduction in G, or its a-subunit mRNA level. Clearly, these more recent data also implicate the cyclase catalytic unit itself as an entity whose malfunction may contribute to the development of a worsening contractile state.
Because it is evident now that the stimulation of adenylyl cyclase is not the only role Gs plays in the myocardium and that ion channels can also be directly gated by Gs, changes in Gs activity in heart failure and ischemia could also influence ion movement in the myocyte. In the heart, in addition to the cAMP-dependent activation of voltage-dependent Developmental changes in Gia and 13 isoform expression have been examined in rat heart during ontogeny, from the neonate to the adult animal.75 Clear differences were observed in the tissue-specific pattern of expression in atria and ventricle, indicating that the stoichiometry of these isoforms may have functional implications during the development of a-adrenergic and parasympathetic signaling pathways in the heart.
The principal isoform in ventricle, Gia2, and its mRNA decreased significantly during development and aging, a process with regulatory consequences that are not understood. Developmental differences in a-adrenoceptor control of cardiac pacemaker activity, however, may be related to the expression of a specific Gi isoform during development.94 Where To Go From Here Quantitation of G protein subunits, G protein activity, receptor numbers, and effector activities has revealed changes in transmembrane signaling in both physiological and pathophysiological processes during development and disease. In addition, quantitation of steady-state mRNA has shed light on mechanisms regulating gene expression at the transcriptional and posttranscriptional levels. However, for more detailed analysis of these mechanisms, the quantitation of mRNA synthesis, processing, and degradation rates as well as factors contributing to translational efficiency of the individual proteins are necessary. Studies in intact organs and intact animals will be required in conjunction with in vitro models using cultured cells. These approaches provide unique and complementary information.
A new approach to addressing the role of changes of the stoichiometry of G proteins and their subunits and isoforms for different effector systems is the transfection of a genetically recombined cDNA encoding for a particular subunit into cultured cells. Through placement of heterologous promoter elements upstream of coding regions of cDNAs that drive high levels of transcription, the overexpression of the encoded polypeptide in these cells is made possible. In addition to the examination of the functional characteristics of a G protein a-subunit, this approach will emphasize the potentially important role of G protein stoichiometry in the regulation of a cellular signaling pathway.
However, with specific regard to cardiac physiology and, in particular, pathophysiology, such in vitro studies are not applicable. First, continuous cardiac cell lines are not available for this kind of approach. More important, cardiac function ultimately must be examined in the intact animal, where the effects of loading and innervation can be monitored. Hence, the establishment of a transgenic animal line overexpressing a particular G protein or receptor isoform in the heart may prove uniquely useful in assessing the tissue-specific functional consequences of changes in gene expression. The altered gene expression would be independent of pathophysiological mechanisms regulating the expression of the native gene. For example, in cardiac hypertrophy in which decreases in the levels of GSa and its mRNA content were observed, the role of increased expression of this protein on cardiac performance could be examined. By the very nature of this method, which uses a heterologous promoter and controlling element (enhancer), this expression would be independent of the transcriptional rate of the endogenous gene. In addition, inducible promoters (like the metallothionein promoter or hormone response elements) could be used to boost the level of gene transcription to higher levels after the onset of a pathophysiological state.
Tissue specificity could be accomplished by inserting a regulatory element that is known to confer expression in a particular cell type. For example, myosin light and heavy chains are regulated in a tissue-and developmentally specific manner, and these promoters may be useful regulatory elements for this kind of approach. 95 The transgenic animal model is not limited to mouse models, which, because of the small size of the animal, would have disadvantages in the assessment of physiological parameters. Data from several groups have indicated that transgenic miniswine can be developed in which the transgene is expressed at high levels.96,97 These animals are sufficiently large to allow careful physiological examinations in the intact animal and thus might be useful for the examination of cardiac performance under physiological and pathophysiological conditions. Furthermore, a larger species would be more amenable to the study of chronic processes (e.g., pressure overload-induced heart failure) that may require months to years to develop, depending on the model. These transgenic models are based on the idea of overexpression of a certain protein in the cardiocyte. However, transgenic animals could also be generated in which the expression of a G protein isoform is reduced or totally abolished. Deletion of the specific allele is accomplished by targeting a mutation to the gene locus using the method of homologous recombination.98 A mutation is generated within the sequence of the desired gene while simultaneously introducing selectable markers that permit the recombination event to be tracked. The mutation causes the disruption of the native gene sequence, which leads to premature termination of gene transcription or mRNA translation. Because the mutated sequence is in large part homologous to the endogenous gene, it will, in rare cases, be integrated into the genome of transfected embryonic stem cells in the place of the desired allele. The selectable markers (i.e., drug resistance genes) are now used to discriminate and select cells that have integrated the mutated sequence at the desired location. This mutated stem cell can now be microinjected into blastocysts; thus, germ-line chimeras can be generated. Finally, by interbreeding heterozygous individuals, one could obtain homozygotes in which both alleles are deleted. This assumes that growth and development can still occur in the absence of the particular gene product. Such deletion models may provide insight into the role and dosage effect of specific gene products in determining the ability of the heart to respond to various pathological states, including volume, pressure overload, and ischemia.
